- Bausch Health Canada announced that Elidel (pimecrolimus) cream is now covered under Alberta’s public drug plan for eligible patients, expanding access to the atopic dermatitis treatment.
- Elidel is indicated as a second-line therapy for short-term and intermittent long-term treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients aged 3 months and older when conventional therapies are unsuitable, ineffective, or not tolerated.
- Available by prescription in Canada since 2003, Elidel is already reimbursed through public drug plans in British Columbia, Saskatchewan, Ontario, and Québec. Alberta’s addition further broadens public access.
- Dermatologists say the coverage gives physicians greater flexibility to tailor treatment and provides patients with a non-corticosteroid topical option when seeking alternatives to topical corticosteroids.
Takeaways:
Alberta’s coverage broadens Elidel’s public-access footprint in Canada and should make it easier for dermatologists to use a non-corticosteroid topical when conventional therapies aren’t suitable, especially for patients who need a steroid-sparing option.
In market terms, the decision mainly extends reimbursement for an established brand rather than creating a new category, but it can still support prescription volume by lowering out-of-pocket barriers and reinforcing Elidel’s role in the atopic dermatitis treatment ladder alongside existing public coverage in British Columbia, Saskatchewan, Ontario, and Québec.
Source: CA Newswire
